Business
Scancell to Present Modi-1 Data at ASCO
Scancell to Present Modi-1 Data at ASCO.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n02 June 2023\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \n \nScancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting\n \nModiFY trial progressing through monotherapy expansion cohorts and combination safety cohorts\n \nFirst patient dosed in Cohort 4 to test high dose Modi-1 in combination with CPI\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present a poster entitled \"Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian cancers: protocol for the ModiFY Phase 1/2 basket clinical trial: report after completion of monotherapy dose-finding\" at the American Society of Clinical Oncology Meeting (ASCO) 2023 Annual Meeting taking place at McCormick Place, Chicago, US between 2-6 June 2023.\n \nThe poster, being presented by Dr Robert Miller, Medical Director, describes the protocol and presents the results after completion of the monotherapy dose-finding and provides an update on patients recruited into the monotherapy dose expansion cohorts and into the checkpoint inhibitor (CPI) combination dose-finding cohort. ModiFY is a first-in-human Phase 1/2 basket trial investigating the use of Modi-1, the first candidate from Scancell's Moditope® platform, to treat four different types of cancer: high grade serous ovarian carcinoma (HGSOC), triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (SCCHN) and renal cell carcinoma (RCC). Data is included up until the date of the poster acceptance by ASCO and concludes that Modi-1 is well tolerated and that the early efficacy data from the monotherapy arms of the trial remain encouraging.\n \nThe ModiFY study is ongoing and recruiting patients into the Phase 2a sub-study investigating Modi-1 monotherapy in dose expansion cohorts. In tandem, recruitment into Cohort 3 to receive treatment with low-dose Modi-1 in combination with standard of care CPI therapy has been completed. Based on review of the safety data from Cohort 3, dose escalation to Cohort 4 has been approved by the Safety Review Board and the first patient has...